AMP highlights PGx NGS workshop
- The Association for Molecular Pathology is spotlighting a pharmacogenomics workshop that walks clinical labs through targeted next-generation sequencing, assay validation, and result reporting for drug-response genes. - The workshop centers on CYP2D6 and other pharmacogenes, using AMP’s Tier 1 and Tier 2 allele framework and Clinical Pharmacogenetics Implementation Consortium guidance to connect sequencing results to prescribing decisions. - AMP’s push builds on years of standardization work around pharmacogene testing and reporting, including joint CYP2D6 recommendations for clinical assays. (amp.org)
Pharmacogenomics asks a simple question: will this patient process a drug normally, too slowly, or too fast based on their DNA. AMP is using a workshop to show clinical labs how to answer that with targeted next-generation sequencing. (amp.org) (amp2024.eventscribe.net) Targeted next-generation sequencing is a focused readout of selected genes rather than the whole genome, like checking a short list instead of every file in a cabinet. In pharmacogenomics, those genes often include drug-metabolism genes such as CYP2D6, where inherited variants can change how patients respond to antidepressants, opioids, beta-blockers, and other medicines. (amp.org) The workshop AMP highlighted covers guideline-driven panel design, wet-lab workflow, validation, variant classification, and clinical reporting. Its session description says the material is aimed at laboratories building or expanding pharmacogenomics testing and connecting results to reporting templates and clinical decision support. (amp2024.eventscribe.net) (amp.org) A central piece is AMP’s tier system for pharmacogenes. Tier 1 alleles are the minimum variants a clinical assay should include, while Tier 2 alleles are additional variants that may be useful but do not meet every criterion for the core panel. (jmdjournal.org) (amp.org) That framework matters most for genes like CYP2D6, which is unusually difficult to test because it has many star-allele haplotypes, copy-number changes, and nearby sequences that can confuse assays. AMP’s 2021 joint recommendation added technical feasibility to its selection criteria because of that complexity. (jmdjournal.org) (amp.org) The reporting side is just as important as the sequencing side. AMP’s materials point labs toward pairing genotype calls with outside prescribing guidance from the Clinical Pharmacogenetics Implementation Consortium, whose CYP2D6 pages link drug-specific recommendations for atomoxetine, tamoxifen, opioids, serotonin reuptake inhibitors, and tricyclic antidepressants. (clinpgx.org) AMP’s pharmacogenetics working group has been building that standardization project gene by gene. The CYP2D6 guidance followed earlier AMP recommendations for CYP2C19, CYP2C9, and genes used in warfarin testing, with the stated goal of making clinical pharmacogenetic assays more consistent across laboratories. (amp.org) The immediate takeaway for labs is practical rather than promotional: choose a defensible allele set, prove the assay works, and report results in a way clinicians can use at the point of prescribing. That is the gap AMP’s workshop is trying to close. (amp.org) (amp2024.eventscribe.net)
